Recce Pharmaceuticals Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 15

Employees

  • Stock Symbol
  • RCE

Stock Symbol

  • Share Price
  • $0.25
  • (As of Monday Closing)

Recce Pharmaceuticals General Information

Description

Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Level 15, 1 Farrer Place
  • Governor Macquarie Tower
  • Sydney, New South Wales 2000
  • Australia
+61 (02)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
ASX
Vertical(s)
Corporate Office
  • Level 15, 1 Farrer Place
  • Governor Macquarie Tower
  • Sydney, New South Wales 2000
  • Australia
+61 (02)

Recce Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Recce Pharmaceuticals Stock Performance

As of 16-Nov-2026, Recce Pharmaceuticals’s stock price is $0.25. Its current market cap is $76.7M with 306M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.25 $0.25 $0.18 - $0.49 $76.7M 306M 260K

Recce Pharmaceuticals Financials Summary

As of 30-Sep-2026, Recce Pharmaceuticals has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV 72,726 87,718 53,864 78,861
EBITDA (8,844) (12,888) (10,902)
Net Income (10,135) (13,864) (11,574)
Total Assets 5,869 8,109 4,257
Total Debt 7,186 7,034 542
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Recce Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Recce Pharmaceuticals‘s full profile, request access.

Request a free trial

Recce Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the developme
Drug Discovery
Sydney, Australia
15 As of 2024

Princeton, NJ
 

Rahway, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Recce Pharmaceuticals Competitors (25)

One of Recce Pharmaceuticals’s 25 competitors is Bristol-Myers Squibb, a Corporation company based in Princeton, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bristol-Myers Squibb Corporation Princeton, NJ
Merck & Co. Corporation Rahway, NJ
Melinta Therapeutics Private Equity-Backed Parsippany, NJ
Gilead Formerly VC-backed Foster City, CA
Gesynta Pharma Venture Capital-Backed Stockholm, Sweden
You’re viewing 5 of 25 competitors. Get the full list »

Recce Pharmaceuticals Patents

Recce Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025905142-A0 Compounds and medical uses thereof Pending 29-Oct-2025
AU-2020900270-A0 Process for preparation of biologically active copolymer Inactive 31-Jan-2020
AU-2021214418-A1 Process for preparation of biologically active copolymer Active 31-Jan-2020
AU-2021214418-B2 Process for preparation of biologically active copolymer Active 31-Jan-2020
CA-3166468-A1 Process for preparation of biologically active copolymer Active 31-Jan-2020 A61K31/765
To view Recce Pharmaceuticals’s complete patent history, request access »

Recce Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Recce Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Recce Pharmaceuticals‘s full profile, request access.

Request a free trial

Recce Pharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Recce Pharmaceuticals’s complete esg history, request access »

Recce Pharmaceuticals FAQs

  • When was Recce Pharmaceuticals founded?

    Recce Pharmaceuticals was founded in 2007.

  • Where is Recce Pharmaceuticals headquartered?

    Recce Pharmaceuticals is headquartered in Sydney, Australia.

  • What is the size of Recce Pharmaceuticals?

    Recce Pharmaceuticals has 15 total employees.

  • What industry is Recce Pharmaceuticals in?

    Recce Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Recce Pharmaceuticals a private or public company?

    Recce Pharmaceuticals is a Public company.

  • What is Recce Pharmaceuticals’s stock symbol?

    The ticker symbol for Recce Pharmaceuticals is RCE.

  • What is the current stock price of Recce Pharmaceuticals?

    As of 16-Nov-2026 the stock price of Recce Pharmaceuticals is $0.25.

  • What is the current market cap of Recce Pharmaceuticals?

    The current market capitalization of Recce Pharmaceuticals is $76.7M.

  • Who are Recce Pharmaceuticals’s competitors?

    Bristol-Myers Squibb, Merck & Co., Melinta Therapeutics, Gilead, and Gesynta Pharma are some of the 25 competitors of Recce Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process